{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"15"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"description":"Number of participants with treatment-related AE is defined as the number of participants who experienced at least one AE assessed as possibly, probably, or definitely related to study treatment according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0.","groups":[{"description":"Participants will receive:\n\n9-ING-41 administered twice per 21-day cycle on Day 1 and Day 4 for up to 1 year. Treatment with 9-ING-41 may continue beyond 1 year in participants with ongoing clinical benefit.\n\nCarboplatin administered once per 21-day cycle on Day 1 for up to 1 year.","id":"OG000","title":"9-ING-41 + Carboplatin (Part I)"},{"description":"Participants will receive:\n\nPembrolizumab 200 mg IV on Day 1 of each 21-day cycle (±3 days) for Cycles 1 and 2 (lead-in therapy).\n\n9-ING-41 administered twice per 21-day cycle on Day 1 and Day 4 for up to 1 year. Treatment with 9-ING-41 may continue beyond 1 year in participants with ongoing clinical benefit.\n\nCarboplatin administered once per 21-day cycle on Day 1 for up to 1 year.","id":"OG001","title":"Pembrolizumab + 9-ING-41 + Carboplatin (Part II)"}],"paramType":"NUMBER","populationDescription":"Arms are defined by treatment assignment. Adenoid cystic carcinoma (ACC) and non-ACC represent disease subgroups within each treatment arm and were not assigned to separate treatment arms. Therefore, participants are reported according to treatment assignment rather than histologic subtype.","reportingStatus":"POSTED","timeFrame":"AEs were assessed at Day 1 and Day 4 of each 21-day treatment cycle; assessed for up to 16.6 months.","title":"Number of Participants With Treatment Related Adverse Events (AE)","type":"SECONDARY","unitOfMeasure":"participants"}